157 related articles for article (PubMed ID: 19031451)
1. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Ushijima N; Koga Y
J Med Virol; 2009 Jan; 81(1):16-26. PubMed ID: 19031451
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N; Suyama H; Yamamoto N
Transl Oncol; 2008 Jul; 1(2):65-72. PubMed ID: 18633461
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.
Koga Y; Naraparaju VR; Yamamoto N
Proc Soc Exp Biol Med; 1999 Jan; 220(1):20-6. PubMed ID: 9893164
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus Type 1.
Yamamoto N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):262-71. PubMed ID: 16545013
[TBL] [Abstract][Full Text] [Related]
8. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N; Naraparaju VR; Srinivasula SM
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1373-8. PubMed ID: 8573395
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus.
Yamamoto N; Urade M
Microbes Infect; 2005 Apr; 7(4):674-81. PubMed ID: 15848273
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Comp Biochem Physiol A Mol Integr Physiol; 2002 May; 132(1):1-8. PubMed ID: 12062184
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.
Albracht SP
Cancer Treat Res Commun; 2022; 31():100537. PubMed ID: 35217488
[TBL] [Abstract][Full Text] [Related]
12. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N; Naraparaju VR; Asbell SO
Cancer Res; 1996 Jun; 56(12):2827-31. PubMed ID: 8665521
[TBL] [Abstract][Full Text] [Related]
13. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Yamamoto N; Naraparaju VR; Moore M; Brent LH
Clin Immunol Immunopathol; 1997 Mar; 82(3):290-8. PubMed ID: 9073553
[TBL] [Abstract][Full Text] [Related]
14. Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor.
Matsuura T; Uematsu T; Yamaoka M; Furusawa K
Int J Oncol; 2004 Mar; 24(3):521-8. PubMed ID: 14767536
[TBL] [Abstract][Full Text] [Related]
15. Is α-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis.
Saburi E; Tavakol-Afshari J; Biglari S; Mortazavi Y
J BUON; 2017; 22(6):1372-1377. PubMed ID: 29332325
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients.
Yamamoto N; Naraparaju VR; Urade M
Cancer Res; 1997 Jan; 57(2):295-9. PubMed ID: 9000571
[TBL] [Abstract][Full Text] [Related]
17. Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer.
Ruggiero M; Ward E; Smith R; Branca JJ; Noakes D; Morucci G; Taubmann M; Thyer L; Pacini S
Anticancer Res; 2014 Jul; 34(7):3569-78. PubMed ID: 24982371
[TBL] [Abstract][Full Text] [Related]
18. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.
Yamamoto N; Naraparaju VR
Immunol Cell Biol; 1998 Jun; 76(3):237-44. PubMed ID: 9682967
[TBL] [Abstract][Full Text] [Related]
19. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
[TBL] [Abstract][Full Text] [Related]
20. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
Yamamoto N; Kumashiro R
J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
